Harpoon Therapeutics, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$100M
Investors
18
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Harpoon Therapeutics, Inc. is an entity organized in Delaware that filed a Form D with the SEC on March 21, 2024. The offering claims Securities Exchange Act of 1934. Harpoon Therapeutics, Inc. reported $100,162,467 sold from 18 investors as of the Form D filed March 21, 2024. The Form D names Cowen and Company, LLC (CRD 7616), associated with None; Canaccord Genuity LLC (CRD 1020), associated with None; H.C. Wainwright & Co., LLC (CRD 375), associated with None as recipients of sales compensation soliciting in CA, CT, FL, MA, NJ, NY. The issuer's address of record is 611 Gateway Boulevard, Suite 400, South San Francisco, CA 94080.
EDGAR Filing Data
Form 15 / Schedule TO — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Mar 21, 2024
Critical / warning
0 / 1
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
closed, lapsed
Latest event Exchange act deregistration · Mar 21, 2024
SEC.govInvestor
- 1 filing event with values and deltas, latest 2024-03-21, and alerts on the next one
- 4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-10-31: 0 related persons added and 2 removed against the filing of 2023-04-07; 9 now listed. The names are in the Terminal feed.
Julie Eastland
Executive Officer, Director · South San Francisco, CA
Joseph Bailes
Director · South San Francisco, CA
Mark Chin
Director · South San Francisco, CA
Jonathan Drachman
Director · South San Francisco, CA
Ronald Hunt
Director · South San Francisco, CA
Scott Myers
Director · South San Francisco, CA
Andrew Robbins
Director · South San Francisco, CA
Lauren Silvernail
Director · South San Francisco, CA
Luke Walker
Executive Officer · South San Francisco, CA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Cowen and Company, LLCCRD 7616 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in CA, CT, FL, MA, NJ, NY
Canaccord Genuity LLCCRD 1020 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in CA, CT, FL, MA, NJ, NY
H.C. Wainwright & Co., LLCCRD 375 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in CA, CT, FL, MA, NJ, NY
Questions About Harpoon Therapeutics, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Harpoon Therapeutics, Inc.?
Harpoon Therapeutics, Inc. is an issuer that filed a Form D with the SEC on March 21, 2024. The filing claims Securities Exchange Act of 1934.
Is Harpoon Therapeutics, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Harpoon Therapeutics, Inc. filed a Form D with the SEC on March 21, 2024 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $100,162,467 sold to 18 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Harpoon Therapeutics, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Harpoon Therapeutics, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Harpoon Therapeutics, Inc. raised?
Harpoon Therapeutics, Inc. reported $100,162,467 sold from 18 investors as of the Form D filed March 21, 2024.
Who is selling Harpoon Therapeutics, Inc. and how are they paid?
The Form D names Cowen and Company, LLC (CRD 7616), associated with None; Canaccord Genuity LLC (CRD 1020), associated with None; H.C. Wainwright & Co., LLC (CRD 375), associated with None as recipients of sales compensation soliciting in CA, CT, FL, MA, NJ, NY.
Who is behind Harpoon Therapeutics, Inc.?
The Form D lists 9 related persons: Julie Eastland, executive officer, director; Joseph Bailes, director; Mark Chin, director; Jonathan Drachman, director; Ronald Hunt, director; Scott Myers, director; Andrew Robbins, director; Lauren Silvernail, director, and 1 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Harpoon Therapeutics, Inc. located?
The issuer's address on its SEC filings is 611 Gateway Boulevard, Suite 400, South San Francisco, CA 94080. Its phone number of record is (650) 443-7400. It is organized under the laws of Delaware.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.